Outpatient Infusion

Tysabri


TYSABRI (also known as Natalizumab)

Mechanism:

Tysabri is an antibody that binds to a cell adhesion molecule called integrin and thereby reduces the ability of inflammatory cells to pass through the lining of the intestines and blood-brain barrier.  Of note, due to the increased risk of a viral infection called progressive multifocal leukoencephalopathy (PML), Tysabri is available only through a special restricted distribution program.

Indications:

  • Relapsing multiple sclerosis
  • Active, severe Crohn’s Disease

Contraindications:

Patients with a history of PML should not be started on Tysabri.

Administration:

Tysabri is typically administered as an infusion over sixty minutes and repeated every 4 weeks.

Copyright by Thrivewell 2017. All rights reserved.